News | March 02, 2021
Piramal Enterprises cashing in on opportunities: ICICI Securities
PEL will explore the PLI scheme and apply if its beneficial.
PEL will explore the PLI scheme and apply if its beneficial.
India business grew 11.8% YoY vs mid-single digit industry growth.
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
The company plans to add 1700 beds by FY27 through the organic route
Both the India and GCC entities will be operated by separate dedicated management teams
Sets price band at ?695 to ?735 per Equity Share
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
Subscribe To Our Newsletter & Stay Updated
